What is HC Wainwright’s Estimate for BEAM FY2025 Earnings?

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright lowered their FY2025 earnings estimates for Beam Therapeutics in a report issued on Wednesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($4.22) for the year, down from their prior forecast of ($3.78). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($3.24) EPS, FY2028 earnings at ($2.11) EPS and FY2029 earnings at ($1.66) EPS.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.12). The business had revenue of $9.70 million during the quarter, compared to the consensus estimate of $12.83 million. Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. Beam Therapeutics’s revenue was down 32.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.17) EPS.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen raised shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price objective on shares of Beam Therapeutics from $48.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, October 9th. Cantor Fitzgerald raised shares of Beam Therapeutics to a “strong-buy” rating in a research report on Monday, July 21st. Finally, Barclays cut their target price on Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.55.

Beam Therapeutics Stock Up 0.3%

Shares of NASDAQ:BEAM opened at $23.15 on Friday. The business’s 50 day moving average is $23.87 and its 200 day moving average is $20.23. Beam Therapeutics has a 12-month low of $13.52 and a 12-month high of $35.25. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -5.23 and a beta of 2.40.

Institutional Investors Weigh In On Beam Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Beam Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company’s stock worth $173,256,000 after purchasing an additional 1,249,303 shares during the period. ARK Investment Management LLC raised its stake in Beam Therapeutics by 4.3% in the 2nd quarter. ARK Investment Management LLC now owns 8,847,841 shares of the company’s stock valued at $150,502,000 after acquiring an additional 367,752 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Beam Therapeutics by 2.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,830,738 shares of the company’s stock valued at $117,242,000 after purchasing an additional 101,294 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its stake in shares of Beam Therapeutics by 10.7% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 4,726,799 shares of the company’s stock valued at $80,403,000 after buying an additional 456,779 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Beam Therapeutics by 72.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,026,701 shares of the company’s stock worth $59,112,000 after buying an additional 1,273,559 shares during the period. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.